Sign Out
Active thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis.
Subarachnoid haemorrhage, the limited clinical experience shows that a reduced risk for rebleeding is offset by an increase in the rate of cerebral ischemia.
Hypersensitivity to Tranexamic acid or any of the ingredients.
In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as measure of toxicity.
